{"id":"NCT02435433","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein","officialTitle":"Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-20","primaryCompletion":"2018-03-15","completion":"2021-11-19","firstPosted":"2015-05-06","resultsPosted":"2019-05-17","lastUpdate":"2023-01-20"},"enrollment":399,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatocellular Carcinoma"],"interventions":[{"type":"DRUG","name":"Ramucirumab","otherNames":["Cyramza","LY3009806"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ramucirumab + Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"label":"Placebo + BSC","type":"PLACEBO_COMPARATOR"},{"label":"Open Label Ramucirumab + BSC","type":"EXPERIMENTAL"},{"label":"Ramucirumab MEE Cohort + BSC","type":"EXPERIMENTAL"},{"label":"Placebo MEE Cohort + BSC","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment \\[MEE\\] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"From Date of Randomization to Death from Any Cause (Up to 28 Months)","effectByArm":[{"arm":"Ramucirumab + Best Supportive Care (BSC)","deltaMin":8.51,"sd":null},{"arm":"Placebo + BSC","deltaMin":7.29,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0199"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":17,"exclusionCount":26},"locations":{"siteCount":131,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Hong Kong","Israel","Italy","Japan","Poland","South Korea","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["36247923","35247922","34795131","33822328","33531690","33188713","32817068","32107609","30665869"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/12euK0N4aQe2aiGqC6GEQ4"]},"adverseEventsSummary":{"seriousAny":{"events":72,"n":197},"commonTop":["Decreased appetite","Hypertension","Fatigue","Oedema peripheral","Proteinuria"]}}